Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure. TORONTO, ONTARIO Monday June 12, 2023 – Braxia Scientific Corp. (“Braxia”, or the“Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with mentalhealth clinics providing innovative ketamine and psilocybin treatments for depression and relateddisorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experienceincreased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased87.2% to 571 from 305 treatments on a year-over-year basis following the completion of constructionand opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterlooclinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214treatments in its first 8 months of operation.“Over...
Braxia Scientific Reports Fiscal 2023 Financial Results
Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoY Company completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023 Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required TORONTO, ONTARIO July 31, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and twelve months ended March 31, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for...
Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals
Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoY TORONTO, ONTARIO Wednesday March 1, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third quarter ended December 31, 2023. The Company also provided an update on the proposed acquisition of the Company by Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) ("Irwin") as outlined in the non-binding Letter of Intent ("LOI") announced January 27, 2023. Complete financial statements along with related management discussion and analysis and the LOI can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system...
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
TORONTO, ONTARIO February 27, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the “LIFE Offering”), resulting in the issuance of 13,658,524 units of the Company (each a “Unit”) at a price of $0.055 per Unit for aggregate proceeds of $751,218.83 (the “LIFE First Tranche”). Each Unit consists of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant entitles its holder to purchase one additional Common Share at an exercise price of $0.07 for a period of 36 months from the date of issue....
Braxia Scientific Announces Offering up to $1.5 Million, Braxia Management to Participate in Concurrent Private Placement
TORONTO, ONTARIO February 7, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce an offering of up to 27,272,727 units of the Company (the “Units”) at a price of $0.055 per Unit for aggregate gross proceeds of up to $1,500,000.00 pursuant to the listed issuer financing exemption (the “LIFE Offering”) and a concurrent private placement of up to 7,272,727 Units (the “Placement Units”) for aggregate gross proceeds of up to $400,000 (the “Concurrent Placement”). Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of...
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development Establishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the US Combined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeutics TORONTO, ONTARIO January 27, 2023 – Braxia Scientific Corp. (“Braxia ”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce it has entered into a non-binding amended and restated letter of intent (“LOI”) for a business combination with Irwin Naturals Inc. (“Irwin”) (CSE: IWIN) (OTC: IWINF) (FRA: 97X). Irwin has been one...
Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America
Braxia Health clinic ketamine treatments up 34.5% YoY in Q2 2023 and revenue up 18% YoY Expanded clinic capacity with new, state-of-the-art clinic opened in Ottawa Closed acquisition of KetaMD and launched new ketamine telemedicine platform in Florida TORONTO, ONTARIO November 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the second quarter ended September 30, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. “We are executing on our vision to increase...
Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home
TORONTO, ONTARIO September 12, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida. KetaMD onboarded new patients and completed initial ketamine treatments. Eligible patients, as determined by one of KetaMD’s licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their home. KetaMD, Inc. (“KetaMD”), a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD). In multiple studies, ketamine...
Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
TORONTO, ONTARIO September 9, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022. CEO Dr. Roger McIntyre will present virtually during the conference providing a update on its recently acquired U.S. based telemedicine business, KetaMD, as well as its progress expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors. The on-demand session will be available at 7:00 a.m. ET Monday September 12, 2022. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright. About Braxia...
Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
TORONTO, ONTARIO August 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the first quarter ended June 30, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. “We are proud to have launched KetaMD in the U.S. so that we can begin addressing the needs of millions lacking access to innovative treatments for mental health disorders such as depression, anxiety, bipolar disorder and post-traumatic stress disorder (PTSD),” said Dr. Roger McIntyre, CEO, Braxia...
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with Plans to Expand Across the U.S.
TORONTO, ONTARIO, Aug. 3, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. ("KetaMD") (the "Transaction"). KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments. KetaMD Logo (CNW Group/Braxia Scientific Corp.) KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression. KetaMD's integration of ketamine and telemedicine is guided by best practices...
Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
Achieved Health Canada Special Access Program approval to provide psilocybin-assisted therapy for depression in Ontario Completed more than 6,000 treatments to date; expanded clinic footprint increasing capacity and greater access to network of mental health specialists Reported positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression TORONTO, ONTARIO July 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its audited financial statements and management discussion and analysis for the year ended March 31, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing...